Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sartorius Stedim Biotech SA Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates


Monday, 28 Jan 2013 11:55pm EST 

Sartorius Stedim Biotech SA announced that for fiscal 2013, it expects revenue to grow by about 8% to 11% in constant currencies, which includes a gain of approx. 3 percentage points resulting from the cooperation with the Swiss life science group Lonza in cell culture media. The Company reported a revenue of EUR544 million for fiscal 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR593 million for fiscal 2013. 

Company Quote

136.1
3.8 +2.87%
11:35am EDT